Barclays
XLO icon

Barclays’s Xilio Therapeutics XLO Stock Holding History

Barclays’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-115
Closed -$1.1K – 5759
2026
Q2 		$1.1K Buy
+115
New +$961 ﹤0.01% 4921
2022
Q2 		– Sell
-89
Closed -$8K – 5299
2022
Q1 		$8K Buy
+89
New +$14.1K ﹤0.01% 4641

Other funds holding XLO

Gilead Sciences
Gilead Sciences Foster City, California $1.46B AUM 71.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Key Financial Inc
Key Financial Inc West Chester, Pennsylvania $614M AUM 14.43% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays's XLO Position: Q3 2026 in Review

Barclays sold out of Xilio Therapeutics (XLO) in Q3 2026, closing a stake of 115 shares — an estimated $1.1K sold.

Barclays first reported a position in XLO in Q1 2022 and held it in 2 quarters. The position peaked at $8K in Q1 2022. 4 funds tracked by Wall St. Rank hold XLO as of Q3 2026.

  • Barclays reported no remaining Xilio Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Barclays sold 115 Xilio Therapeutics shares in Q3 2026, an estimated $1.1K.
  • Barclays first reported a position in Xilio Therapeutics in Q1 2022 and held it in 2 quarters.
  • Barclays's Xilio Therapeutics position peaked at $8K in Q1 2022.
  • 4 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.